⌕
Beam Therapeutics · BEAM · Nasdaq
Tenet 61 · Solid
Compare
$20.65−1.38%At closeTenet 61 · Solid
$20.65−0.29 (−1.38%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Beam Therapeutics (BEAM) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is BEAM's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 14:52 ET
Beam Therapeutics Inc. (BEAM) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript

Beam Therapeutics Inc. (BEAM) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript…

BEAM −1.4% todayRead at source ↗
● Seeking AlphaNov 12, 2026 · 12:50 ET
Beam Therapeutics: Market Selling Promising Data Readouts Doesn't Add Up

Beam Therapeutics receives a Buy rating, driven by promising data across AATD, GSDIa, and SCD, and robust funding. BEAM's risto-cel SCD therapy shows strong efficacy but faces market skepticism due to challenging treatme…

BEAM −1.4% todayRead at source ↗
● Zacks Investment ResearchNov 11, 2026 · 14:11 ET
BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study

Beam Therapeutics reports positive BEACON study results for risto-cel in sickle cell disease, paving the way for a potential FDA filing by year-end 2026.…

BEAM −1.4% todayRead at source ↗
● GlobeNewsWireNov 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease

BEACON Trial Achieved Primary Efficacy Endpoint of Freedom from Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months, Based on Independently Adjudicated Results, and Met All Primary Safety Endpoints at …

BEAM −1.4% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting

BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom…

BEAM −1.4% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 09:16 ET
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $1.1 per share a year ago.…

BEAM −1.4% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio

Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in First Half of 2027…

BEAM −1.4% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 05:51 ET
Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?

Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near t…

BEAM −1.4% todayRead at source ↗
● Seeking AlphaOct 27, 2026 · 13:10 ET
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript

Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript…

BEAM −1.4% todayRead at source ↗
● MarketBeatOct 27, 2026 · 11:07 ET
Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance

Beam Therapeutics NASDAQ: BEAM reported initial clinical data from its Phase I/II trial of BEAM-301, an investigational base-editing therapy for glycogen storage disease type 1A (GSD1a), showing dose-dependent improvemen…

BEAM −1.4% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress

In the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following Treatment  Safety Profile of BEAM-301 Consistent with LNP…

BEAM −1.4% todayRead at source ↗
● Defense WorldOct 19, 2026 · 04:22 ET
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells $589,250.00 in Stock

Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) CEO John Evans sold 25,000 shares of the business's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $23.57, for a tot…

BEAM −1.4% todayRead at source ↗
● The Motley FoolOct 17, 2026 · 21:00 ET
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?

Cathie Wood owns Beam shares worth roughly $220 million, at the stock's current price. All of the company's revenue is collaboration revenue.…

BEAM −1.4% todayRead at source ↗
● PRNewsWireOct 15, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyt…

BEAM −1.4% todayRead at source ↗
● GlobeNewsWireOct 13, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress

BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Impr…

BEAM −1.4% todayRead at source ↗
● PRNewsWireOct 8, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyto…

BEAM −1.4% todayRead at source ↗
● PRNewsWireOct 1, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM).  Such investors are advised to contact Danielle Peyt…

BEAM −1.4% todayRead at source ↗
● Seeking AlphaSep 29, 2026 · 07:30 ET
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress

Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances. BEAM's pipeline leadership in AATD gene editing (BEAM-302) offers first-mover advantage, while R…

BEAM −1.4% todayRead at source ↗
● PRNewsWireSep 24, 2026 · 17:34 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM).…

BEAM −1.4% todayRead at source ↗

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just BEAM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.